Related Experiment Video
Updated: Jun 13, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Expression of PD-L1 and PD-L2 and Their Association with IFN-γ/STAT1/STAT3 Signaling in Human Clear Cell Renal Cell
Gábor Kónya1,2, Ali Shammas1,2, Erzsébet Szabó3,4
1Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary.
Abstract:
Background: Programmed cell death protein-1 (PD-1) and its ligands, PD-L1 and PD-L2, constitute a central immune checkpoint pathway that regulates T-cell activity and tumor immune escape, while their relationship with STAT signaling remains incompletely understood in ccRCC. Methods: We analyzed 27 paired ccRCC and adjacent non-tumorous human kidney tissue samples. mRNA levels of PD-1, PD-L1, PD-L2, STAT1, and STAT3 were quantified by RT-qPCR. In addition, representative human ccRCC cell lines (CAKI-2 and A-498) were treated with IFN-γ to assess the time-dependent modulation of immune checkpoint molecules and STAT pathway activation. Results: PD-L1 and PD-L2 were significantly upregulated in tumor tissues compared with adjacent normal kidney tissue. Exploratory observation suggests grade dependent increase. Whereas PD-1 was predominantly downregulated, IFN-γ treatment induced a rapid transcriptional upregulation of PD-L1 and PD-L2 in RCC cell lines, with maximal protein accumulation observed at 72 h. STAT1, but not STAT3, exhibited dynamic induction following IFN-γ stimulation, showing temporal association with PD-L1 and PD-L2 upregulation, indicating cell-line-specific regulatory effects. Correlation analyses confirmed a strong correlation between PD-1 and its ligands, whereas STAT1 and STAT3 expression showed no direct association with PD-L1 or PD-L2 levels in cancer samples. Conclusions: Our findings demonstrate that PD-L1 and PD-L2 are frequently upregulated in ccRCC and dynamically regulated by IFN-γ/STAT1-dependent signaling. Our results provide additional insight into the mechanisms of immune escape and underscore the potential of integrated profiling of PD-1 ligands and STAT signaling to guide personalized immunotherapeutic strategies in ccRCC.
Insights
Programmed cell death protein-1 (PD-1) ligands PD-L1 and PD-L2 are upregulated in kidney cancer. Interferon-gamma and STAT1 signaling dynamically regulate these immune checkpoints, offering insights for personalized immunotherapy.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Programmed cell death protein-1 (PD-1) and its ligands (PD-L1, PD-L2) are key regulators of T-cell activity and tumor immune escape.
- The precise relationship between these immune checkpoints and STAT signaling in clear cell renal cell carcinoma (ccRCC) requires further elucidation.
Purpose of the Study:
- To investigate the expression of PD-1, PD-L1, PD-L2, STAT1, and STAT3 in ccRCC tissues.
- To examine the impact of interferon-gamma (IFN-γ) on immune checkpoint molecule expression and STAT pathway activation in ccRCC cell lines.
Main Methods:
- Analysis of mRNA levels of PD-1, PD-L1, PD-L2, STAT1, and STAT3 in 27 paired ccRCC and adjacent non-tumorous human kidney tissues using RT-qPCR.
- Treatment of ccRCC cell lines (CAKI-2, A-498) with IFN-γ to assess time-dependent modulation of immune checkpoint molecules and STAT pathway activation.
Main Results:
- PD-L1 and PD-L2 were significantly upregulated in ccRCC tissues compared to normal kidney tissue, with a potential grade-dependent increase.
- IFN-γ treatment induced rapid upregulation of PD-L1 and PD-L2 in ccRCC cell lines, peaking at 72 hours.
- STAT1, but not STAT3, showed dynamic induction following IFN-γ stimulation, correlating with PD-L1/PD-L2 upregulation, while STAT1/STAT3 expression lacked direct association with PD-L1/PD-L2 levels in cancer samples.
Conclusions:
- PD-L1 and PD-L2 are frequently upregulated in ccRCC and are dynamically regulated by IFN-γ/STAT1-dependent signaling.
- These findings enhance understanding of immune escape mechanisms in ccRCC.
- Integrated profiling of PD-1 ligands and STAT signaling may guide personalized ccRCC immunotherapeutic strategies.
